British Journal of Cancer最新文献

筛选
英文 中文
Association of metabolic obesity phenotypes with risk of overall and site-specific cancers: a systematic review and meta-analysis of cohort studies 代谢性肥胖表型与总体癌症和特定部位癌症风险的关系:队列研究的系统回顾和荟萃分析。
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-24 DOI: 10.1038/s41416-024-02857-7
Yahya Mahamat-saleh, Dagfinn Aune, Heinz Freisling, Sheetal Hardikar, Rola Jaafar, Sabina Rinaldi, Marc J. Gunter, Laure Dossus
{"title":"Association of metabolic obesity phenotypes with risk of overall and site-specific cancers: a systematic review and meta-analysis of cohort studies","authors":"Yahya Mahamat-saleh, Dagfinn Aune, Heinz Freisling, Sheetal Hardikar, Rola Jaafar, Sabina Rinaldi, Marc J. Gunter, Laure Dossus","doi":"10.1038/s41416-024-02857-7","DOIUrl":"10.1038/s41416-024-02857-7","url":null,"abstract":"Adiposity is a known risk factor for certain cancers; however, it is not clear whether the risk of cancer differs between individuals with high adiposity but different metabolic health status. The aim of this systematic literature review and meta-analysis of cohort studies was to evaluate associations between metabolic obesity phenotypes and overall and site-specific cancer risk. PubMed and Embase databases were used to identify relevant cohort studies up to the 6th of June 2023. Random-effects models were used to estimate summary relative risks (SRRs) and 95% confidence intervals (CIs) for the association between metabolic obesity phenotypes and cancer risk. Certainty of evidence was assessed using the Cochrane methods and the GRADE tool. This study is registered with PROSPERO, number CRD42024549511. A total of 15,556 records were screened, and 31 publications covering 15 unique cohort studies were included in this analysis. Of these studies, 22 were evaluated as being at low risk of bias and 9 at moderate risk of bias. Compared to metabolically healthy normal-weight individuals (MHNW), metabolically unhealthy overweight/obese (MUOW/OB) individuals had a higher risk of overall (SRR = 1.21, 95% CI = 1.02–1.44, n = 3 studies, high certainty) and obesity-related cancers (SRR = 1.42, 95% CI = 1.15–1.74, n = 3, very low certainty). Specifically, MUOW/OB individuals were at higher risk of cancers of the postmenopausal breast (SRR = 1.32, 95% CI = 1.17–1.48, n = 7, low certainty), colorectum (SRR = 1.24, 95% CI = 1.16–1.31, n = 6, moderate certainty), endometrium (SRR = 2.31, 95% CI = 2.08–2.57, n = 4, high certainty), thyroid (SRR = 1.42, 95% CI = 1.29–1.57, n = 4, moderate certainty), kidney (SRR = 1.71, 95% CI = 1.40–2.10, n = 3, low certainty), pancreas (SRR = 1.35, 95% CI = 1.24–1.47, n = 3, high certainty), liver (SRR = 1.81, 95% CI = 1.36–2.42, n = 2, moderate certainty), gallbladder (SRR = 1.42, 95% CI = 1.17–1.73, n = 2, high certainty), bladder (SRR = 1.36, 95% CI = 1.19–1.56, n = 2, moderate certainty), and stomach (SRR = 1.50, 95% CI = 1.12–2.01, n = 2, high certainty). In addition, we found elevated risks of most of these cancers among individuals classified as MUNW and MHOW/OB phenotypes compared to those with MHNW phenotype. Our stratified analyses according to metabolic obesity phenotypes suggested that the elevated risks of some cancers were stronger in individuals with MUOW/OB versus those with MHOW/OB or MUNW phenotypes. These findings suggest that both higher adiposity and metabolic dysfunction were independently associated with increased risk of several cancers, with the strongest associations generally observed among those with both metabolic dysfunction and obesity.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02857-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142341977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its molecular mechanism in malignant progression GFPT2:间皮瘤诊断和预后的新型生物标志物及其恶性进展的分子机制。
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-24 DOI: 10.1038/s41416-024-02830-4
Jia Wei, Suiqing Zhou, Gang Chen, Tingting Chen, Yan Wang, Jue Zou, Fang Zhou, Jiali Liu, Qixing Gong
{"title":"GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its molecular mechanism in malignant progression","authors":"Jia Wei, Suiqing Zhou, Gang Chen, Tingting Chen, Yan Wang, Jue Zou, Fang Zhou, Jiali Liu, Qixing Gong","doi":"10.1038/s41416-024-02830-4","DOIUrl":"10.1038/s41416-024-02830-4","url":null,"abstract":"Mesothelioma (MESO) is an insidious malignancy with a complex diagnosis and a poor prognosis. Our study unveils Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2) as a valuable diagnostic and prognostic marker for MESO, exploring its role in MESO pathogenesis. We utilised tissue samples and clinicopathologic data to evaluate the diagnostic and prognostic significance of GFPT2 as a biomarker for MESO. The role of GFPT2 in the malignant progression of MESO was investigated through in vitro and in vivo experiments. The activation of NF-κB-p65 through O-GlcNAcylation at Ser75 was elucidated using experiments like HPLC-QTRAP-MS/MS and mass spectrometry analysis. The study demonstrates that GFPT2 exhibits a sensitivity of 92.60% in diagnosing MESO. Overexpression of it has been linked to an unfavourable prognosis. Through rigorous verification, we have confirmed that elevated GFPT2 levels drive malignant proliferation, invasiveness, and metastasis in MESO. At the molecular level, GFPT2 augments p65 O-GlcNAcylation, orchestrating its nuclear translocation and activating the NF-κB signalling pathway. Our insights suggest GFPT2’s potential as a distinctive biomarker for MESO diagnosis and prognosis, and as an innovative therapeutic target, offering a new horizon for identification and treatment strategies in MESO management.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142341980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer HER2 阳性胃癌患者术前化疗中额外使用曲妥珠单抗的肿瘤浸润免疫细胞特征及其变化。
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-23 DOI: 10.1038/s41416-024-02835-z
Cong Chen, Jing Han, Qifei He, Qian Yao, Xueying Wang, Zuofu Peng, Yu Sun, Jiafu Ji, Xiaofang Xing
{"title":"Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer","authors":"Cong Chen, Jing Han, Qifei He, Qian Yao, Xueying Wang, Zuofu Peng, Yu Sun, Jiafu Ji, Xiaofang Xing","doi":"10.1038/s41416-024-02835-z","DOIUrl":"10.1038/s41416-024-02835-z","url":null,"abstract":"HER2(+) gastric cancer (GC) can benefit from trastuzumab. However, the impact of additional trastuzumab in preoperative treatment on immune cells remains largely unknown. In cohort I, immune cells were detected by immunohistochemistry in 1321 patients. Then 88 HER2(+) patients received preoperative therapy were collected as cohort II. Immune cell profiles and changes were analyzed in paired pre- and post-operative specimens using multiple immunohistochemistry staining. In the treatment-naive GC patients (n = 1002), CD3+ and CD8+ T cell infiltration was significantly lower in the HER2(+) GC patients together with higher FoxP3+ T cells compared with HER2(−). However, FoxP3+ T and CD20+ B cell infiltration was significantly higher in HER2(+) GC after neoadjuvant chemotherapy (n = 319). The trastuzumab-exposed group had higher CD8+ T and lower FoxP3+ T cell infiltration and CD8+ T cell was even more significant in responders. Additionally, tertiary lymphoid structure (TLS) density increased in invasion margin of residual tumors. Patients with lower TLS in the tumor core or lower FoxP3+ T cells had better overall survival in the trastuzumab-exposed group. Addition of trastuzumab modulates the immune microenvironment, suggesting the potential mechanism of the favorable outcome of anti-HER2 therapy and providing a theoretical rationale for the combinational immunotherapy in resectable HER2(+) GC patients.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02835-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer SON 是促进乳腺癌中 ErbB2 和 ErbB3 表达的重要 RNA 剪接因子。
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-23 DOI: 10.1038/s41416-024-02853-x
Joshua B. Phillips, Seong-Sik Park, Cheng-Han Lin, Juyoung Cho, Sangbin Lim, Ritu Aurora, Jin-Hwan Kim, Anusha Angajala, Bohye Park, Joshua K. Stone, Bin Wang, Andrea G. Kahn, Ssang-Taek Steve Lim, Jung-Hyun Kim, Eun-Young Erin Ahn, Ming Tan
{"title":"SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer","authors":"Joshua B. Phillips, Seong-Sik Park, Cheng-Han Lin, Juyoung Cho, Sangbin Lim, Ritu Aurora, Jin-Hwan Kim, Anusha Angajala, Bohye Park, Joshua K. Stone, Bin Wang, Andrea G. Kahn, Ssang-Taek Steve Lim, Jung-Hyun Kim, Eun-Young Erin Ahn, Ming Tan","doi":"10.1038/s41416-024-02853-x","DOIUrl":"10.1038/s41416-024-02853-x","url":null,"abstract":"In breast cancer, ErbB receptors play a critical role, and overcoming drug resistance remains a major challenge in the clinic. However, intricate regulatory mechanisms of ErbB family genes are poorly understood. Here, we demonstrate SON as an ErbB-regulatory splicing factor and a novel therapeutic target for ErbB-positive breast cancer. SON and ErbB expression analyses using public database, patient tissue microarray, and cell lines were performed. SON knockdown assessed its impact on cell proliferation, apoptosis, kinase phosphorylation, RNA splicing, and in vivo tumour growth. RNA immunoprecipitation was performed to measure SON binding. SON is highly expressed in ErbB2-positive breast cancer patient samples, inversely correlating with patient survival. SON knockdown induced intron retention in selective splice sites within ErbB2 and ErbB3 transcripts, impairing effective RNA splicing and reducing protein expression. SON disruption suppressed downstream kinase signalling of ErbB2/3, including the Akt, p38, and JNK pathways, with increased vulnerability in ErbB2-positive breast cancer cells compared to ErbB2-negative cells. SON silencing in ErbB2-positive breast cancer xenografts led to tumour regression in vivo. We identified SON as a novel RNA splicing factor that plays a critical role in regulating ErbB2/3 expression, suggesting SON is an ideal therapeutic target in ErbB2-positive breast cancers.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer 靶向致癌原粘连蛋白的双修饰反义寡核苷酸治疗胃癌。
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-20 DOI: 10.1038/s41416-024-02859-5
Mitsuro Kanda, Yuuya Kasahara, Dai Shimizu, Takahiro Shinozuka, Masahiro Sasahara, Shunsuke Nakamura, Yohei Iguchi, Masahisa Katsuno, Yasuhiro Kodera, Satoshi Obika
{"title":"Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer","authors":"Mitsuro Kanda, Yuuya Kasahara, Dai Shimizu, Takahiro Shinozuka, Masahiro Sasahara, Shunsuke Nakamura, Yohei Iguchi, Masahisa Katsuno, Yasuhiro Kodera, Satoshi Obika","doi":"10.1038/s41416-024-02859-5","DOIUrl":"10.1038/s41416-024-02859-5","url":null,"abstract":"The objective of this study was to develop an innovative treatment strategy utilizing antisense oligonucleotides (ASOs) that target the gene encoding protocadherin alpha 11 (PCDHA11) and to elucidate the role of PCDHA11 in gastric cancer cells. We designed and screened 54 amido-bridged nucleic acid (AmNA)-modified ASOs, selecting them based on PCDHA11-knockdown efficacy, in vitro and in vivo activity, and off-target effects. We assessed the impact of AmNA-modified anti-PCDHA11 ASOs on cellular functions and signaling pathways, and investigated the effects of Pcdha11 deficiency in mice. AmNA-modified anti-PCDHA11 ASOs significantly reduced the proliferation of gastric cancer cells and other solid tumors, whereas overexpression of PCDHA11 enhanced cell proliferation. The selected ASOs inhibited cellular functions related to the metastatic potential of gastric cancer cells, including migration, invasiveness, spheroid formation, and cancer stemness. Our findings revealed that AmNA-modified anti-PCDHA11 ASOs disrupted the AKT/mTOR, Wnt/β-catenin, and JAK/STAT signaling pathways. In mouse models of peritoneal metastasis (gastric and pancreatic cancer), systemic metastasis, and established subcutaneous tumors, administration of AmNA-modified anti-PCDHA11 ASOs inhibited tumor growth. ASO treatment induced reversible, dose- and sequence-dependent liver damage. Pcdha11-deficient mice demonstrated normal reproductive, organ, and motor functions. AmNA-modified anti-PCDHA11 ASOs offer a promising therapeutic strategy for the treatment of gastric cancer and other solid malignancies.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC 早期非小细胞肺癌预后中癌症干细胞检测方法的比较
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-20 DOI: 10.1038/s41416-024-02839-9
Boutaîna Chandouri, Thomas Naves, May Yassine, Léa Ikhlef, Jérémy Tricard, Alain Chaunavel, Zeinab Homayed, Julie Pannequin, Nicolas Girard, Stéphanie Durand, Vincent Carré, Fabrice Lalloué
{"title":"Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC","authors":"Boutaîna Chandouri, Thomas Naves, May Yassine, Léa Ikhlef, Jérémy Tricard, Alain Chaunavel, Zeinab Homayed, Julie Pannequin, Nicolas Girard, Stéphanie Durand, Vincent Carré, Fabrice Lalloué","doi":"10.1038/s41416-024-02839-9","DOIUrl":"10.1038/s41416-024-02839-9","url":null,"abstract":"Despite advances in diagnosis and treatment in lung cancer, therapies still fail to improve patient management due to resistance mechanisms and relapses. As Cancer stem cells (CSCs) directly contribute to tumor growth and therapeutic resistance, their clinical detection represents a major challenge. However specific and additional CSC markers lack. Thus, our aim was to achieve selective detection of CSCs with specific glycan patterns and assess the CSCs burden to predict the risk of relapse in NSCLC tumors. The lung CSCs detection and sorting with a lectin MIX were assessed and compared to CD133 in vitro. Then, its putative role as CSC biomarker was evaluated in vivo and its clinical significance on 221 NSCLC patients. We showed a significant CSCs enrichment in the MIX+ sorted fraction compared to CD133+ cells and confirmed its high tumorigenic capacity. The MIX prognostic value on the overall survival from early stages patients was validated suggesting its potential for detecting CSCs directly linked to tumor aggressiveness. The MIX could be more relevant for detecting and sorting CSCs than CD133. Moreover, its prognosis value could enable clinicians to better classify early-stage patients at high risk of relapse in order to tailor therapeutic decisions.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02839-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank 在英国生物库中验证用于预测上皮性输卵管卵巢癌风险的 BOADICEA 模型
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-18 DOI: 10.1038/s41416-024-02851-z
Xin Yang, Yujia Wu, Lorenzo Ficorella, Naomi Wilcox, Joe Dennis, Jonathan Tyrer, Tim Carver, Nora Pashayan, Marc Tischkowitz, Paul D. P. Pharoah, Douglas F. Easton, Antonis C. Antoniou
{"title":"Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank","authors":"Xin Yang, Yujia Wu, Lorenzo Ficorella, Naomi Wilcox, Joe Dennis, Jonathan Tyrer, Tim Carver, Nora Pashayan, Marc Tischkowitz, Paul D. P. Pharoah, Douglas F. Easton, Antonis C. Antoniou","doi":"10.1038/s41416-024-02851-z","DOIUrl":"10.1038/s41416-024-02851-z","url":null,"abstract":"The clinical validity of the multifactorial BOADICEA model for epithelial tubo-ovarian cancer (EOC) risk prediction has not been assessed in a large sample size or over a longer term. We evaluated the model discrimination and calibration in the UK Biobank cohort comprising 199,429 women (733 incident EOCs) of European ancestry without previous cancer history. We predicted 10-year EOC risk incorporating data on questionnaire-based risk factors (QRFs), family history, a 36-SNP polygenic risk score and pathogenic variants (PV) in six EOC susceptibility genes (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and PALB2). Discriminative ability was maximised under the multifactorial model that included all risk factors (AUC = 0.68, 95% CI: 0.66–0.70). This model was well calibrated in deciles of predicted risk with calibration slope=0.99 (95% CI: 0.98–1.01). Discriminative ability was similar in women younger or older than 60 years. The AUC was higher when analyses were restricted to PV carriers (0.76, 95% CI: 0.69–0.82). Using relative risk (RR) thresholds, the full model classified 97.7%, 1.7%, 0.4% and 0.2% women in the RR < 2.0, 2.0 ≤ RR < 2.9, 2.9 ≤ RR < 6.0 and RR ≥ 6.0 categories, respectively, identifying 9.1 of incident EOC among those with RR ≥ 2.0. BOADICEA, implemented in CanRisk ( www.canrisk.org ), provides valid 10-year EOC risks and can facilitate clinical decision-making in EOC risk management.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02851-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testing of rapid evaporative mass spectrometry for histological tissue classification and molecular diagnostics in a multi-site study 在一项多站点研究中测试用于组织学组织分类和分子诊断的快速蒸发质谱法
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-18 DOI: 10.1038/s41416-024-02739-y
Martin Kaufmann, Pierre-Maxence Vaysse, Adele Savage, Loes F. S. Kooreman, Natasja Janssen, Sonal Varma, Kevin Yi Mi Ren, Shaila Merchant, Cecil Jay Engel, Steven W. M. Olde Damink, Marjolein L. Smidt, Sami Shousha, Hemali Chauhan, Evdoxia Karali, Emine Kazanc, George Poulogiannis, Gabor Fichtinger, Boglárka Tauber, Daniel R. Leff, Steven D. Pringle, John F. Rudan, Ron M. A. Heeren, Tiffany Porta Siegel, Zoltán Takáts, Júlia Balog
{"title":"Testing of rapid evaporative mass spectrometry for histological tissue classification and molecular diagnostics in a multi-site study","authors":"Martin Kaufmann, Pierre-Maxence Vaysse, Adele Savage, Loes F. S. Kooreman, Natasja Janssen, Sonal Varma, Kevin Yi Mi Ren, Shaila Merchant, Cecil Jay Engel, Steven W. M. Olde Damink, Marjolein L. Smidt, Sami Shousha, Hemali Chauhan, Evdoxia Karali, Emine Kazanc, George Poulogiannis, Gabor Fichtinger, Boglárka Tauber, Daniel R. Leff, Steven D. Pringle, John F. Rudan, Ron M. A. Heeren, Tiffany Porta Siegel, Zoltán Takáts, Júlia Balog","doi":"10.1038/s41416-024-02739-y","DOIUrl":"10.1038/s41416-024-02739-y","url":null,"abstract":"While REIMS technology has successfully been demonstrated for the histological identification of ex-vivo breast tumor tissues, questions regarding the robustness of the approach and the possibility of tumor molecular diagnostics still remain unanswered. In the current study, we set out to determine whether it is possible to acquire cross-comparable REIMS datasets at multiple sites for the identification of breast tumors and subtypes. A consortium of four sites with three of them having access to fresh surgical tissue samples performed tissue analysis using identical REIMS setups and protocols. Overall, 21 breast cancer specimens containing pathology-validated tumor and adipose tissues were analyzed and results were compared using uni- and multivariate statistics on normal, WT and PIK3CA mutant ductal carcinomas. Statistical analysis of data from standards showed significant differences between sites and individual users. However, the multivariate classification models created from breast cancer data elicited 97.1% and 98.6% correct classification for leave-one-site-out and leave-one-patient-out cross validation. Molecular subtypes represented by PIK3CA mutation gave consistent results across sites. The results clearly demonstrate the feasibility of creating and using global classification models for a REIMS-based margin assessment tool, supporting the clinical translatability of the approach.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02739-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors 结直肠癌中的 DNA 修复依赖性免疫原性责任:错误带来的机遇
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-13 DOI: 10.1038/s41416-024-02848-8
V. Amodio, P. P. Vitiello, A. Bardelli, G. Germano
{"title":"DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors","authors":"V. Amodio, P. P. Vitiello, A. Bardelli, G. Germano","doi":"10.1038/s41416-024-02848-8","DOIUrl":"10.1038/s41416-024-02848-8","url":null,"abstract":"Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. Chemotherapy continues to serve as the primary treatment modality, while immunotherapy is largely ineffective for the majority of CRC patients. Seminal discoveries have emphasized that modifying DNA damage response (DDR) mechanisms confers both cell-autonomous and immune-related vulnerabilities across various cancers. In CRC, approximately 15% of tumours exhibit alterations in the mismatch repair (MMR) machinery, resulting in a high number of neoantigens and the activation of the type I interferon response. These factors, in conjunction with immune checkpoint blockades, collectively stimulate anticancer immunity. Furthermore, although less frequently, somatic alterations in the homologous recombination (HR) pathway are observed in CRC; these defects lead to genome instability and telomere alterations, supporting the use of poly (ADP-ribose) polymerase (PARP) inhibitors in HR-deficient CRC patients. Additionally, other DDR inhibitors, such as Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitors, have shown some efficacy both in preclinical models and in the clinical setting, irrespective of MMR proficiency. The aim of this review is to elucidate how preexisting or induced vulnerabilities in DNA repair pathways represent an opportunity to increase tumour sensitivity to immune-based therapies in CRC.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02848-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Live birth and maternity outcome in childhood and adolescent cancer survivors under 18 years at diagnosis: a 40-year population-based cohort study 确诊时未满 18 岁的儿童和青少年癌症幸存者的活产和分娩结果:一项为期 40 年的人群队列研究
IF 6.4 1区 医学
British Journal of Cancer Pub Date : 2024-09-12 DOI: 10.1038/s41416-024-02818-0
W. H. Wallace, T. W. Kelsey, D. Morrison, R. A. Anderson
{"title":"Live birth and maternity outcome in childhood and adolescent cancer survivors under 18 years at diagnosis: a 40-year population-based cohort study","authors":"W. H. Wallace, T. W. Kelsey, D. Morrison, R. A. Anderson","doi":"10.1038/s41416-024-02818-0","DOIUrl":"10.1038/s41416-024-02818-0","url":null,"abstract":"Survival from childhood and adolescent cancer has increased, but the chance of a livebirth in female survivors under 18 years at diagnosis may be reduced. We performed a national population-based analysis, including all female cancer survivors diagnosed in Scotland before the age of 18 years between 1981 and 2012. Scottish Cancer Registry records were linked to Scottish maternity records. Females from the exposed group with no pregnancies before cancer diagnosis (n = 2118) were compared with three general population controls matched for age and year of diagnosis. The cumulative incidence of a livebirth for all diagnoses was reduced to 37% (95% CI 33–40%) for cancer survivors at 30 years of age vs 58% (57–60%) for controls. The deficit varying by diagnosis: for lymphoid leukaemia, the cumulative incidence at 30 years was 29% (23–36%) vs 57% (52–61%) for controls with similar deficits in CNS tumours and retinoblastoma. There was a steady improvement in the chance of livebirth in those diagnosed more recently. We have shown a reduced chance of livebirth in female survivors of cancer diagnosed before age 18. The deficit is present for all diagnoses.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02818-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142187715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信